Etzer Darout
Stock Analyst at BMO Capital
(3.83)
# 778
Out of 4,412 analysts
64
Total ratings
39.22%
Success rate
13.22%
Average return
Main Sectors:
Top Industries:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZN AstraZeneca | Maintains: Outperform | $80 → $82 | $75.17 | +9.09% | 4 | Apr 26, 2024 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $18 → $25 | $8.46 | +195.51% | 4 | Apr 26, 2024 | |
| NVS Novartis AG | Maintains: Market Perform | $114 → $116 | $97.44 | +19.05% | 2 | Apr 24, 2024 | |
| BNTX BioNTech SE | Maintains: Outperform | $127 → $123 | $87.21 | +41.04% | 2 | Mar 21, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $18 → $19 | $4.91 | +286.97% | 2 | Mar 15, 2024 | |
| CTMX CytomX Therapeutics | Maintains: Market Perform | $3.3 → $3.25 | $1.59 | +104.40% | 7 | Mar 12, 2024 | |
| MGNX MacroGenics | Maintains: Outperform | $18 → $24 | $14.56 | +64.84% | 6 | Mar 8, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Outperform | $16 → $26 | $14.71 | +76.75% | 5 | Mar 4, 2024 | |
| MRUS Merus | Maintains: Outperform | $49 → $58 | $45.04 | +28.77% | 4 | Feb 29, 2024 | |
| XNCR Xencor | Maintains: Outperform | $38 → $34 | $19.98 | +70.17% | 2 | Feb 28, 2024 | |
| NUVL Nuvalent | Maintains: Outperform | $93 → $102 | $66.86 | +52.56% | 4 | Feb 28, 2024 | |
| ARVN Arvinas | Maintains: Outperform | $89 → $90 | $32.37 | +178.04% | 1 | Feb 28, 2024 | |
| FATE Fate Therapeutics | Maintains: Market Perform | $6 → $7 | $3.80 | +84.21% | 6 | Feb 27, 2024 | |
| GMAB Genmab | Upgrades: Outperform | $46 → $48 | $28.15 | +70.52% | 2 | Feb 23, 2024 | |
| CCCC C4 Therapeutics | Maintains: Outperform | $18 → $16 | $6.17 | +159.32% | 2 | Nov 3, 2023 | |
| IVA Inventiva | Reiterates: Buy | $12 | $3.25 | +269.23% | 2 | Sep 1, 2023 | |
| FHTX Foghorn Therapeutics | Maintains: Outperform | $20 → $19 | $5.49 | +246.08% | 2 | Apr 25, 2023 | |
| EXEL Exelixis | Initiates: Outperform | $28 | $23.70 | +18.14% | 1 | Jun 24, 2022 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Buy | $170 | $143.31 | +18.62% | 2 | Feb 3, 2022 | |
| VERV Verve Therapeutics | Initiates: Buy | n/a | $6.16 | - | 1 | Jul 12, 2021 | |
| AKRO Akero Therapeutics | Initiates: Buy | n/a | $19.74 | - | 1 | Feb 26, 2021 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | n/a | $24.46 | - | 1 | Sep 9, 2020 | |
| ACRS Aclaris Therapeutics | Maintains: Outperform | n/a | $1.20 | - | 1 | Mar 28, 2018 |
AstraZeneca
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $75.17
Upside: +9.09%
Acrivon Therapeutics
Apr 26, 2024
Maintains: Outperform
Price Target: $18 → $25
Current: $8.46
Upside: +195.51%
Novartis AG
Apr 24, 2024
Maintains: Market Perform
Price Target: $114 → $116
Current: $97.44
Upside: +19.05%
BioNTech SE
Mar 21, 2024
Maintains: Outperform
Price Target: $127 → $123
Current: $87.21
Upside: +41.04%
Terns Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $18 → $19
Current: $4.91
Upside: +286.97%
CytomX Therapeutics
Mar 12, 2024
Maintains: Market Perform
Price Target: $3.3 → $3.25
Current: $1.59
Upside: +104.40%
MacroGenics
Mar 8, 2024
Maintains: Outperform
Price Target: $18 → $24
Current: $14.56
Upside: +64.84%
Y-mAbs Therapeutics
Mar 4, 2024
Maintains: Outperform
Price Target: $16 → $26
Current: $14.71
Upside: +76.75%
Merus
Feb 29, 2024
Maintains: Outperform
Price Target: $49 → $58
Current: $45.04
Upside: +28.77%
Xencor
Feb 28, 2024
Maintains: Outperform
Price Target: $38 → $34
Current: $19.98
Upside: +70.17%
Nuvalent
Feb 28, 2024
Maintains: Outperform
Price Target: $93 → $102
Current: $66.86
Upside: +52.56%
Arvinas
Feb 28, 2024
Maintains: Outperform
Price Target: $89 → $90
Current: $32.37
Upside: +178.04%
Fate Therapeutics
Feb 27, 2024
Maintains: Market Perform
Price Target: $6 → $7
Current: $3.80
Upside: +84.21%
Genmab
Feb 23, 2024
Upgrades: Outperform
Price Target: $46 → $48
Current: $28.15
Upside: +70.52%
C4 Therapeutics
Nov 3, 2023
Maintains: Outperform
Price Target: $18 → $16
Current: $6.17
Upside: +159.32%
Inventiva
Sep 1, 2023
Reiterates: Buy
Price Target: $12
Current: $3.25
Upside: +269.23%
Foghorn Therapeutics
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $5.49
Upside: +246.08%
Exelixis
Jun 24, 2022
Initiates: Outperform
Price Target: $28
Current: $23.70
Upside: +18.14%
Alnylam Pharmaceuticals
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $143.31
Upside: +18.62%
Verve Therapeutics
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $6.16
Upside: -
Akero Therapeutics
Feb 26, 2021
Initiates: Buy
Price Target: n/a
Current: $19.74
Upside: -
Mirum Pharmaceuticals
Sep 9, 2020
Maintains: Buy
Price Target: n/a
Current: $24.46
Upside: -
Aclaris Therapeutics
Mar 28, 2018
Maintains: Outperform
Price Target: n/a
Current: $1.20
Upside: -